Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

What Was Tested

In this phase 4 trial, researchers set out to test Tirzepatide.

Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers.

It had two arms (groups): Tirzepatide + Lifestyle Intervention (experimental) and Lifestyle Intervention (active comparator).

The registry classes the interventions as behavioral and drug.

More on the Plan

Eligible obese patients (or overweight patients with a weight-related comorbidity) with symptomatic paroxysmal or persistent AF undergoing catheter ablation will be screened within 28 days before the procedure.

After ablation with restoration of sinus rhythm, participants will be randomized 1:1 to (a) tirzepatide plus standardized lifestyle intervention and standard AF management, or (b) standardized lifestyle intervention and standard AF management alone.

Randomization is stratified by study center, AF type (paroxysmal/persistent), baseline BMI, and diabetes status.

Both groups receive guideline-directed periprocedural anticoagulation, standardized antiarrhythmic drug (AAD) use, an individualized exercise prescription, a modified Mediterranean diet (target intake = total energy expenditure - 500 kcal), and management of smoking, alcohol, comorbidities, sleep, and obstructive sleep apnea (OSA).

Who Took Part

The registry lists 710 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥18 years and ≤75 years at the time of screening. Body weight criteria (aligned with NMPA-approved tirzepatide indication) meeting at least one of the following:. Failed response to or intolerance of at least one antiarrhythmic drug (AAD), or explicit patient preference for a rhythm control strategy. Undergoing catheter ablation for AF at a participating center, with confirmed successful restoration of sinus rhythm at the end of the procedure (as determined by the operator). Willing and able to understand the study procedures, provide written informed consent, and comply with all protocol requirements including 12-month follow-up visits.

The full record lists 7 inclusion and 19 exclusion criteria; among the exclusions: long-standing persistent af: continuous af duration ≥5 years prior to enrollment; prior catheter ablation for af or atrial flutter at any time; left atrial anteroposterior diameter \>55 mm (by transthoracic echocardiography at screening).

How the Study Was Run

Design: randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Tirzepatide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-09-01 with completion listed for 2029-09-01.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Number of Participants With Recurrence of Atrial Fibrillation, Atrial Flutter, or Atrial Tachycardia (time frame: Day 91 through Week 52 after catheter ablation).

It also tracked 9 secondary outcomes, for example Percentage of Monitoring Time Spent in Atrial Fibrillation (AF Burden), Change in body weight, Change in BMI, Change in waist circumference, Change in left atrial volume index (LAVI) and Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Tirzepatide in 710 people.

With 710 participants it is a large trial for this field.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.